iX Biopharma’s New Wafer Revolutionizes NAD+ Supplementation

iX Biopharma Ltd. (SG:42C) has released an update.

iX Biopharma Ltd has revealed a pharmacokinetic study indicating that their SL-NAD+ wafer can effectively deliver NAD+ directly into cells via sublingual administration, challenging previous assumptions about NAD+ cellular entry. The study showed rapid absorption with significant bioavailability, suggesting a convenient alternative to IV therapy for NAD+ supplementation. These findings position SL-NAD+ as a potentially superior method for enhancing NAD+ levels without relying on precursors.

For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.